The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.
暂无分享,去创建一个
[1] C. Orlandini,et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] L. Gullo,et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. , 2000, The New England journal of medicine.
[3] C. Orlandini,et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. , 2000, American journal of clinical oncology.
[4] B. Simon,et al. Treatment of Neuroendocrine GEP Tumours with Somatostatin Analogues , 2000, Digestion.
[5] Corinaldesi,et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR , 2000, Alimentary pharmacology & therapeutics.
[6] O. Schillaci,et al. Long-term octreotide treatment of metastatic carcinoid tumor. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] U. Mansmann,et al. Ultra-High-Dose Lanreotide Treatment in Patients with Metastatic Neuroendocrine Gastroenteropancreatic Tumors , 1999, Digestion.
[8] C. Beglinger,et al. Somatostatin and Octreotide: Physiological Background and Pharmacological Application , 1999, Digestion.
[9] E. D. de Vries,et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Beglinger,et al. The Role of Octreotide in the Treatment of Gastroenteropancreatic Endocrine Tumors , 1999, Digestion.
[11] J. Ajani,et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Eriksson,et al. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Ong,et al. The octreotide suppression test and [111In‐DTPA‐D‐Phe1]‐octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment , 1998, Clinical endocrinology.
[14] Eva Forssell-Aronsson,et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. , 1998, British Journal of Cancer.
[15] K. Öberg,et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] I. Lancranjan,et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. , 1996, Metabolism: clinical and experimental.
[17] R. Jian,et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. , 1996, Gut.
[18] K. Öberg. Neuroendocrine gastrointestinal tumours , 1996 .
[19] R. Arnold,et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. , 1996, Gut.
[20] L. Mariani,et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group , 1996, Cancer.
[21] V. Mazzaferro,et al. The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. , 1996, Digestion.
[22] I. Lancranjan,et al. Sandostatin LAR®: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients , 1995 .
[23] G. Bell,et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Gregor. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment. , 1994, Digestion.
[25] B. Wiedenmann,et al. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. , 1994, European journal of cancer.
[26] R. Arnold,et al. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. , 1994, Digestion.
[27] E. Krenning,et al. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.
[28] A. Schally,et al. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. , 1991, Cancer research.
[29] J. Reubi,et al. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. , 1987, The Journal of clinical endocrinology and metabolism.
[30] P. Marbach,et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.
[31] S. Efendić,et al. EFFICACY OF SOMATOSTATIN IN A PATIENT WITH CARCINOID SYNDROME , 1978, The Lancet.